TAK-954 in Critically Ill Participants With Enteral Feeding Intolerance (EFI) (NCT03477903) | Clinical Trial Compass
TerminatedPhase 2
TAK-954 in Critically Ill Participants With Enteral Feeding Intolerance (EFI)
Stopped: Insufficient enrollment; No safety concerns
United States1 participantsStarted 2018-08-25
Plain-language summary
The purpose of this study is to assess the treatment effect of intravenous TAK-954 in improving the average daily protein adequacy received through enteral nutrition in critically-ill participants developing EFI.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Has at least a size 12-(french size) Fr nasogastric or orogastric tube with its tip at least 10 centimeter (cm) below the esophagogastric junction confirmed radiologically (the tip of the tube must be in the body or the antrum of the stomach and not in the fundus).
✓. Is intubated and mechanically ventilated in the ICU.
✓. Is expected to remain alive, mechanically ventilated, and receive continuous enteral feeding for \>=48 hours following randomization.
✓. Have EFI, defined as a single GRV measurement of \>=250 mL with vomiting/retching within the last 24 hours, or a single GRV measurement of \>=500 mL with or without vomiting/retching within the last 24 hours.
Exclusion criteria
✕. Is under consideration for withdrawal of life-sustaining treatments within the next 72 hours.
✕. Has had major esophageal or gastric surgery or direct luminal trauma on this admission (participants with lower abdominal surgery are not excluded unless enteral feeding is contraindicated).
✕. Has mechanical bowel obstruction, short bowel syndrome, or the presence of an active gastric pacemaker.
✕. Have pre-existing hepatic disease that meets Child-Pugh Class B (moderate; total score 7 to 9 points) or C (severe; total score 10 to 15 points).
✕. Has been admitted primarily for treatment of a drug overdose.
✕. Has a presence of a post-pyloric tube in place at Randomization that may be used for enteral nutrition.
What they're measuring
1
Average Daily Protein Adequacy Over the First 5 Days of Treatment